Trial Profile
Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2022
Price :
$35
*
At a glance
- Drugs Branebrutinib (Primary) ; Caffeine; Digoxin; Flurbiprofen; Folinic acid; Methotrexate; Midazolam; Montelukast; Omeprazole; Pravastatin
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 04 Jun 2022 Results assessing the DDI potential of branebrutinib when co-administered with potential concomitant medications in 3 single-sequence, cross-over clinical studies in healthy participants presented at the 23rd Annual Congress of the European League Against Rheumatism
- 13 Dec 2017 Status changed from not yet recruiting to completed.
- 02 May 2017 New trial record